SCHEMBL212639

SCHEMBL212639

CC(C)(C)OP(=O)(Br)OC(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL486485 0.72 TSHR (0.31)
SCHEMBL19348741 0.69
Fluoride SCHEMBL12079669 0.69
Phosphine SCHEMBL28531842 0.69 TSHR (0.35)
SCHEMBL517524 0.69
SCHEMBL12604843 0.69
SCHEMBL4253621 0.69
SCHEMBL332472 0.67
SCHEMBL14035030 0.67 CTSA (0.36)
SCHEMBL1634012 0.67 TP53 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3890749-B1 CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS AGENTS FOR TREATMENT OF CANCER SUMITOMO PHARMA AMERICA INC (US) 2025-10-29 EP disclosed
US-20250197432-A1 CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of Cancer SUMITOMO PHARMA ONCOLOGY INC (US) 2025-06-19 US disclosed
US-12077554-B2 CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer SUMITOMO PHARMA ONCOLOGY, INC. (US) 2024-09-03 US disclosed
US-20230250116-A1 CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of Cancer SUMITOMO PHARMA ONCOLOGY, INC. 2023-08-10 US disclosed
WO-2023134465-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF 上海艾力斯医药科技股份有限公司 2023-07-20 WO disclosed
US-11530231-B2 CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer SUMITOMO PHARMA ONCOLOGY, INC. (US) 2022-12-20 US disclosed
US-20210332071-A1 CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of Cancer SUMITOMO PHARMA ONCOLOGY, INC. 2021-10-28 US disclosed
EP-3890749-A1 CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS AGENTS FOR TREATMENT OF CANCER Sumitomo Dainippon Pharma Oncology, Inc. (US) 2021-10-13 EP disclosed
US-11034710-B2 CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) 2021-06-15 US disclosed
US-20200255462-A1 CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS AGENTS FOR TREATMENT OF CANCER SUMITOMO PHARMA ONCOLOGY, INC. 2020-08-13 US disclosed
WO-2009023193-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INCORPORATED (US) 2009-02-19 WO disclosed
WO-2009023193-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INCORPORATED (US) 2009-02-19 WO disclosed
WO-2008076265-A1 MONOPHOSPHATES AS MUTUAL PRODRUGS OF ANTI-INFLAMMATORY SIGNAL TRANSDUCTION MODULATORS (AISTM'S) AND β-AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION GILEAD SCIENCES, INC. (US) 2008-06-26 WO disclosed
WO-2008076269-A2 MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND β-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS GILEAD SCIENCES, INC. (US) 2008-06-26 WO disclosed
EP-1893220-A1 SUBSTITUTED PHENYLPHOSPHATES AS MUTUAL PRODRUGS OF STEROIDS AND BETA -AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION Gilead Sciences, Inc. (US) 2008-03-05 EP disclosed
WO-2006138212-A1 SUBSTITUTED PHENYLPHOSPHATES AS MUTUAL PRODRUGS OF STEROIDS AND β -AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION GILEAD SCIENCES, INC. (US) 2006-12-28 WO disclosed
WO-2005063777-A1 BENZYLPHOSPHATE AND SUBSTITUTED BENZYLPHOSPHATE PRODRUGS FOR THE TREATMENT OF PULMONARY INFLAMMATION CORUS PHARMA (US) 2005-07-14 WO disclosed
EP-1156054-B1 DRUGS CONTAINING PHOSPHORIC ACID DERIVATIVES AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2004-04-14 EP disclosed
US-6495533-B1 TUMOR NECROSIS FACTOR INHIBITORS; RHEUMATOID ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE, HEPATITIS, SEPSIS, HEMORRHAGIC SHOCK, MULTIPLE SCLEROSIS, CEREBRAL INFARCTION, DIABETES, INTERSTITIAL PNEUMONIA, PAIN, HIV ONO PHARMACEUTICAL CO., LTD. (JP) 2002-12-17 US disclosed
EP-1156054-A1 DRUGS CONTAINING PHOSPHORIC ACID DERIVATIVES AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-11-21 EP disclosed